You are here

New small molecule inhibitors of arenaviruses

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI112045-01
Agency Tracking Number: R41AI112045
Amount: $598,297.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: R
Solicitation Number: PA10-124
Timeline
Solicitation Year: 2015
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-02-15
Award End Date (Contract End Date): 2017-01-31
Small Business Information
MICROBIOTIX, INC, Worcester, MA, 01605-4307
DUNS: 158864715
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 LIJUN RONG
 (312) 355-0203
 lijun@uic.edu
Business Contact
 TERRY BOWLIN
Phone: (508) 757-2800
Email: tbowlin@microbiotix.com
Research Institution
 UNIVERSITY OF ILLINOIS AT CHICAGO
 CHICAGO, IL, 60612-7224
 Nonprofit college or university
Abstract
DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenaviruses on public health and biodefense readiness coupled with limited treatment options to combat arenavirus infections underscore the importance of developing novel and effective strategies to combat arenaviruses especially LASV and MACV New small molecule inhibitors would be of paramount importance for use during arenaviral outbreaks or bioterrorist attacks This application defines a plan to develop potent small molecule inhibitors which block entry of LASV and MACV Entry of LASV and MACV into the hosts is mediated by a single viral glycoprotein GP which is considered one of the major therapeutic targets GP consists of three subunits GP GP and a stable signal peptide SSP GP is responsible for receptor binding and host tropism while GP mediates viral cell membrane fusion and viral entry We have used an HTS protocol targeting GP mediated viral entry to screen a small molecule library and we have identified compounds that inhibit entry of LASV and MACV IC values M These hit compounds exhibit selectivity for arenavirus entry The overall objective of this Phase I application is to develop these inhibitors as potentia antiviral therapeutics This application will focus on the following three specific aims Synthesize structurally diverse analogs of the anti arenavirus MBX hit series based on structure activity relationships SARs to improve potency and selectivity Select LASV MACV inhibitors with in vitro ADME properties suitable for i v and oral dosing Validate the lead inhibitor candidates in the infectious assays and investigate the mechanism of action MOA of the LASV MACV inhibitors PUBLIC HEALTH RELEVANCE This project is to discover and develop small molecule entry inhibitors for arenaviruses The proposed research will help to develop potential antiviral therapeutics

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government